UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------------------------------------------------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO Section 240.13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 3)
BIOMARIN PHARMACEUTICAL INC
----------------------------------------------
(Name of Issuer)
COMMON STOCK
-----------------------------------------------
(Title of Class of Securities)
09061G101
---------------------
(CUSIP Number)
DECEMBER 31, 2017
---------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[x] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
Page 1 of 5 Pages
-------------------------------------------------------------------------------
CUSIP No.: 09061G101 13G Page 2 of 5 Pages
.................................................................................
1. Names of Reporting Persons
Sands Capital Management, LLC
.................................................................................
2. Check the Appropriate Box if a Member of a Group (a) [ ]
(b) [ ]
NOT APPLICABLE
.................................................................................
3. SEC Use Only
.................................................................................
4. Citizenship or Place of Organization
Delaware, United States
.................................................................................
Number of 5. Sole Voting Power: 5,447,596
Shares
Beneficially ................................................................
Owned by Each
Reporting 6. Shared Voting Power: -0-
Person With ................................................................
7. Sole Dispositive Power: 7,726,778
................................................................
8. Shared Dispositive Power: -0-
.................................................................................
9. Aggregate Amount Beneficially Owned by Each Reporting Person
7,726,778
.................................................................................
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
NOT APPLICABLE
.................................................................................
11. Percent of Class Represented by Amount in Row (9)
4.4% (1)
.................................................................................
12. Type of Reporting Person:
IA
______________________________
(1) Based on 175,621,277 shares of common stock outstanding as reported in the
Issuer's Form 10-Q as of October 25, 2017.
-------------------------------------------------------------------------------
CUSIP No.: 09061G101 13G Page 3 of 5 Pages
Item 1(a) Name of Issuer:
BIOMARIN PHARMACEUTICAL INC
Item 1(b) Address of Issuer's Principal Executive Offices:
770 Lindaro Street, San Rafael, California
Item 2(a) Name of Person Filing:
SANDS CAPITAL MANAGEMENT, LLC
Item 2(b) Address of Principal Business Office, or if None, Residence:
1000 WILSON BLVD., SUITE 3000, ARLINGTON, VA 22209
Item 2(c) Citizenship:
DELAWARE, UNITED STATES
Item 2(d) Title of Class of Securities:
COMMON STOCK
Item 2(e) CUSIP Number: 09061G101
Item 3 If this statement is filed pursuant to Sections 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o);
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c);
(d) [ ] Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C 80a-8);
(e) [X] An investment adviser in accordance with Section
240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
Section 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
Section 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act (15 U.S.C. 80a-3);
(j) [ ] A non-U.S. institution in accordance with Section
240.13d-1(b)(1)(ii)(J);
(k) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with Section
240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
-------------------------------------------------------------------------------
CUSIP No.: 09061G101 13G Page 4 of 5 Pages
Item 4. Ownership
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 7,726,778
(b) Percent of class: 4.4%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 5,447,596
(ii) Shared power to vote or to direct the vote: None
(iii) Sole power to dispose or to direct the disposition of: 7,726,778
(iv) Shared power to dispose or to direct the disposition of: None
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the
following [ X ].
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company or
Control Person.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not Applicable.
-------------------------------------------------------------------------------
CUSIP No.: 09061G101 13G Page 5 of 5 Pages
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were acquired and are held in the ordinary course
of business and were not acquired and are not held for the purpose of or with
the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect, other than
activities solely in connection with a nomination under Section 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Sands Capital Management, LLC
Date: February 14, 2018
By: /s/ Lisa M. Grozio
----------------------
Name: Lisa M. Grozio
Title: Chief Compliance Officer